Merit Medical Systems Net Common Equity Issued/Repurchased 2010-2025 | MMSI
Merit Medical Systems annual/quarterly net common equity issued/repurchased history and growth rate from 2010 to 2025. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
- Merit Medical Systems net common equity issued/repurchased for the quarter ending March 31, 2025 was $0.013B, a 70.14% increase year-over-year.
- Merit Medical Systems net common equity issued/repurchased for the twelve months ending March 31, 2025 was $0.080B, a 81.84% increase year-over-year.
- Merit Medical Systems annual net common equity issued/repurchased for 2024 was $0.041B, a 162.5% increase from 2023.
- Merit Medical Systems annual net common equity issued/repurchased for 2023 was $0.016B, a 22.35% decline from 2022.
- Merit Medical Systems annual net common equity issued/repurchased for 2022 was $0.02B, a 5.8% decline from 2021.
Merit Medical Systems Annual Net Common Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$41 |
| 2023 |
$16 |
| 2022 |
$20 |
| 2021 |
$21 |
| 2020 |
$7 |
| 2019 |
$6 |
| 2018 |
$215 |
| 2017 |
$144 |
| 2016 |
$5 |
| 2015 |
$7 |
| 2014 |
$8 |
| 2013 |
$4 |
| 2012 |
$4 |
| 2011 |
$95 |
| 2010 |
$2 |
| 2009 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$5.835B |
$1.357B |
|
Merit Medical Systems, Inc. provides various peripheral and cardiac intervention products to cure cardiac conditions specific to interventional cardiology and electrophysiology. The company offers products focused in five core product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, cardiovascular and critical care as well as endoscopy. However, the company operates in two revenue segments: Cardiovascular and Endoscopy Devices.
|
